258 related articles for article (PubMed ID: 21658324)
1. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
2. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
[TBL] [Abstract][Full Text] [Related]
3. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
4. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
Kivisäkk P; Alm GV; Fredrikson S; Link H
Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
[TBL] [Abstract][Full Text] [Related]
6. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta.
Bertolotto A; Sala A; Caldano M; Capobianco M; Malucchi S; Marnetto F; Gilli F
J Immunol Methods; 2007 Apr; 321(1-2):19-31. PubMed ID: 17335844
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
Shokrollahi Barough M; Ashtari F; Sadat Akhavi M; Asghari N; Mosayebi G; Mirmohammadkhani M; Kokhaei N; Bahraminia F; Ajami A; Kokhaei P
Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to interferon beta in patients with multiple sclerosis receiving CinnoVex, rebif, and betaferon.
Zare N; Zarkesh-Esfahani SH; Gharagozloo M; Shaygannejad V
J Korean Med Sci; 2013 Dec; 28(12):1801-6. PubMed ID: 24339712
[TBL] [Abstract][Full Text] [Related]
10. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
11. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
[TBL] [Abstract][Full Text] [Related]
12. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta.
Brickelmaier M; Hochman PS; Baciu R; Chao B; Cuervo JH; Whitty A
J Immunol Methods; 1999 Jul; 227(1-2):121-35. PubMed ID: 10485260
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies to interferon beta in multiple sclerosis: analytical evaluation for validation of a cytopathic effect assay.
Massart C; Gibassier J; Oger J; Le Page E; Edan G
Clin Chim Acta; 2007 Feb; 377(1-2):185-91. PubMed ID: 17123498
[TBL] [Abstract][Full Text] [Related]
14. Characterization and quantitation of aggregates and particles in interferon-β products: potential links between product quality attributes and immunogenicity.
Barnard JG; Babcock K; Carpenter JF
J Pharm Sci; 2013 Mar; 102(3):915-28. PubMed ID: 23233295
[TBL] [Abstract][Full Text] [Related]
15. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
16. Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta.
Gilli F; De La Torre AL; Royce DB; Pachner AR
Int Immunopharmacol; 2018 Sep; 62():1-6. PubMed ID: 29960044
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of interferon beta: differences among products.
Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
[TBL] [Abstract][Full Text] [Related]
18. The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels.
Grossberg SE; Kawade Y; Grossberg LD
J Interferon Cytokine Res; 2009 Feb; 29(2):93-104. PubMed ID: 19000020
[TBL] [Abstract][Full Text] [Related]
19. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.
Runkel L; De Dios C; Karpusas M; Baker D; Li Z; Zafari M; Betzenhauser M; Muldowney C; Miller S; Redlich PN; Grossberg SE; Whitty A; Hochman PS
J Interferon Cytokine Res; 2001 Nov; 21(11):931-41. PubMed ID: 11747625
[TBL] [Abstract][Full Text] [Related]
20. Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
Jensen PEH; Warnke C; Ingenhoven K; Piccoli L; Gasis M; Hermanrud C; Fernandez-Rodriguez BM; Ryner M; Kramer D; Link J; Ramanujam R; Auer M; Buck D; Grummel V; Bertotti E; Fissolo N; Oliver-Martos B; Nytrova P; Khalil M; Guger M; Rathmaier S; Sievers-Stober C; Lindberg RLP; Hässler S; Bachelet D; Aktas O; Donnellan N; Lawton A; Hemmer B; Havrdova EK; Kieseier B; Hartung HP; Comabella M; Montalban X; Derfuss T; Sellebjerg F; Dönnes P; Pallardy M; Spindeldreher S; Broët P; Deisenhammer F; Fogdell-Hahn A; Sorensen PS;
J Neuroimmunol; 2019 Jan; 326():19-27. PubMed ID: 30447419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]